



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

October 7, 2024

Mark S. Shearman, Ph.D.  
Chief Executive Officer  
APRINOIA Therapeutics Inc.  
245 Main Street, 2nd Floor  
Cambridge, MA 02142

**Re: APRINOIA Therapeutics Inc.  
Amendment No. 4 to Registration Statement on Form F-1  
Exhibit Nos. 10.7, 10.8, 10.9, 10.10, 10.11, 10.12, 10.13, 10.14, 10.15, 10.16, 10.17, 10.18,  
10.19, 10.20 and 10.21  
Filed September 11, 2024  
File No. 333-276696**

Dear Dr. Shearman:

We have concluded our assessment of your redacted exhibits for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Will H. Cai, Esq.